Top

Published in:

01-04-2009 | Gastrointestinal Oncology

Perioperative Chemotherapy for Gastric Cancer: How Should We Measure the Efficacy?

Authors: Roberto Persiani, MD, Stefano Rausei, MD, Alberto Biondi, MD, Domenico D’Ugo, FACS

Published in: Annals of Surgical Oncology | Issue 4/2009

Excerpt

We are grateful to Dr. Fatourou et al. for having commented on our work, since this gives us the opportunity to clarify some key points of our rationale in selecting gastric cancer patients to be enrolled in a protocol of perioperative chemotherapy.1 …

Fatourou E, Macheras A, Misiakos EP, Liakakos T. Perioperative chemotherapy for gastric cancer. Ann Surg Oncol. 2009;16:226–7.PubMedCrossRef

Wanebo HJ, Kennedy BJ, Chmiel J, Steele G Jr, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993;218:583–92.PubMedCrossRef

Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87:236–42.PubMedCrossRef

Lim L, Michael M, Mann GB, Leong T. Adjuvant therapy in gastric cancer. J Clin Oncol. 2005;23:6220–32.PubMedCrossRef

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.PubMedCrossRef

Ajani JA, Ota DM, Jessup JM, Ames FC, McBride C, Boddie A, et al. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer. 1991;68:1501–6.PubMedCrossRef

Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst. 1993;85:1839–44.PubMedCrossRef

Fink U, Schuhmacher C, Stein HJ, Busch R, Feussner H, Dittler HJ, et al. Preoperative chemotherapy for stage III–IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg. 1995;82:1248–52.PubMedCrossRef

Crookes P, Leichman CG, Leichman L, Tan M, Laine L, Stain S, et al. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Cancer. 1997;79:1767–75.PubMedCrossRef

10.

Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, et al. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol. 1999;17:2403–11.PubMed

11.

Schuhmacher CP, Fink U, Becker K, Busch R, Dittler HJ, Mueller J, et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer. 2001;91:918–27.PubMedCrossRef

12.

Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 2004;30:643–9.PubMedCrossRef

13.

Barone C, Cassano A, Pozzo C, D’Ugo D, Schinzari G, Persiani R, et al. Long term follow up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer. Oncology. 2004;67:48–53.PubMedCrossRef

14.

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.PubMedCrossRef

15.

D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240:808–16.PubMedCrossRef

16.

Marrelli D, De Stefano A, de Manzoni G, Morgagni P, Di Leo A, Roviello F. Prediction of recurrence after radical surgery for gastric cancer: a scoring system obtained from a prospective multicenter study. Ann Surg. 2005;241:247–55.PubMedCrossRef

17.

D’Ugo DM, Coppola R, Persiani R, Ronconi P, Caracciolo F, Picciocchi A. Immediately preoperative laparoscopic staging for gastric cancer. Surg Endosc. 1996;10:996–9.PubMedCrossRef

18.

D’Ugo DM, Pende V, Persiani R, Rausei S, Picciocchi A. Laparoscopic staging of gastric cancer: an overview. J Am Coll Surg. 2003;196:965–74.PubMedCrossRef

19.

Harewood GC. Treatment of gastric cancer. N Engl J Med. 2006;355:1386.PubMedCrossRef

20.

D’Ugo D, Persiani R, Rausei S, Biondi A, Vigorita V, Boccia S, et al. Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer. Eur J Surg Oncol. 2006;32:1105–9.PubMedCrossRef

21.

Becker K, Mueller JD, Schuhmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521–30.PubMedCrossRef

22.

Persiani R, D’Ugo D, Rausei S, Sermoneta D, Barone C, Pozzo C, et al. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy. J Surg Oncol. 2005;89:227–36.PubMedCrossRef

23.

Yonemura Y, Kinoshita K, Fujimura T, Fushida S, Sawa T, Matsuki N, et al. Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. Hepatogastroenterology. 1996;43:1260–72.PubMed

24.

Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999;80:269–72.PubMedCrossRef

25.

Boige V, Pignon J, Saint-Aubert B, Lasser P, Conroy T, Bouché O, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol. 2007;25:4510.

26.

Mansour JC, Coit D. Appropriate treatment for patients with gastric cancer (author reply). Ann Surg Oncol. 2008;15:1798–9.CrossRef

27.

Persiani R, Rausei S, Pozzo C, Biondi A, Barone C, Cananzi FC, et al. 7-Year survival results of perioperative chemotherapy with epidoxorubicin, etoposide, and cisplatin (EEP) in locally advanced resectable gastric cancer: up-to-date analysis of a phase-II study. Ann Surg Oncol. 2008;15:2146–52.PubMedCrossRef

28.

Lordick F, Ott K, Krause BJ, Becker K, Stein HJ, Lorenzen S, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797–805.PubMedCrossRef

Title: Perioperative Chemotherapy for Gastric Cancer: How Should We Measure the Efficacy?
Authors: Roberto Persiani, MD
Stefano Rausei, MD
Alberto Biondi, MD
Domenico D’Ugo, FACS
Publication date: 01-04-2009
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 4/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-008-0310-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Perioperative Chemotherapy for Gastric Cancer: How Should We Measure the Efficacy?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2009

Extent of Thyroidectomy and Lymphadenectomy in 254 Patients With Papillary Thyroid Microcarcinoma: A Single-Institution Experience

In Reply: In Favor of Axillary Lymph Node Dissection: Need for a Pragmatic View

Method of Detection of Initial Recurrence of Stage II/III Cutaneous Melanoma: Analysis of the Utility of Follow-Up Staging

Positive Regulation of Human Telomerase Reverse Transcriptase Gene Expression and Telomerase Activity by DNA Methylation in Pancreatic Cancer

Detection and Functional Analysis of Tumor Infiltrating T-Lymphocytes (TIL) in Liver Metastases from Colorectal Cancer

Optimizing Melphalan Pharmacokinetics in Regional Melanoma Therapy: Does Correcting for Ideal Body Weight Alter Regional Response or Toxicity?